V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015306 | 160007582 | 1.76 | 93.3 | Curative (C) | 2016-04-28 | 2016-05-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100439448 |
| 160015308 | 160007583 | 1.49 | 27 | Curative (C) | 2021-01-18 | 2021-01-20 | Trial Unspecified | Y | N | DOXORUBICIN | 101227183 |
| 160015310 | 160007585 | 1.65 | 49 | Palliative (P) | 2017-04-25 | 2017-05-17 | DOXORUBICIN | 02 | Y | DOXORUBICIN | 100669557 |
| 160015311 | 160007586 | 1.51 | 87 | Palliative (P) | null | 2017-06-22 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100437290 |
| 160015315 | 160007587 | 1.82 | 44.7 | null | 2018-11-03 | 2018-12-07 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100338080 |
| 160015317 | 160007588 | 1.57 | 63.2 | null | null | 2016-10-10 | Carboplatin + Paclitaxel (weekly) | null | null | CARBOPLATIN + PACLITAXEL | 100239304 |
| 160015318 | 160007589 | 1.66 | 87.4 | null | 2019-04-06 | 2019-04-13 | CARBOPLATIN + PACLITAXEL | 02 | Y | CARBOPLATIN + PACLITAXEL | 101106853 |
| 160015319 | 160007590 | 0.88 | 63 | Neo-adjuvant (N) | 2017-10-05 | 2017-10-18 | STS Non-Rhabdo EpSSG 2005 IVA | 02 | N | TRIAL | 100595510 |
| 160015321 | 160007591 | 1.66 | 60 | Palliative (P) | 2017-05-29 | 2017-06-25 | LANREOTIDE | null | N | DOXORUBICIN + OLARATUMAB | 101463496 |
| 160015327 | 160007592 | 1.79 | 55.1 | null | null | 2017-06-17 | Cisplatin + Pemetrexed | null | null | CISPLATIN + PEMETREXED | 100742271 |
| 160015329 | 160007593 | 1.71 | 74.9 | Curative (C) | 2019-11-28 | 2020-01-03 | ETOP 13-18 BEAT-meso Trial | 02 | N | MELPHALAN | 101018744 |
| 160015332 | 160007595 | 1.81 | 14 | Curative (C) | 2018-04-24 | 2018-05-03 | null | 02 | N | ABIRATERONE | 101434084 |
| 160015333 | 160007596 | 1.74 | 118.6 | Palliative (P) | 2021-01-12 | 2021-01-12 | NIVOLUMAB | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100437773 |
| 160015337 | 160007597 | 1.72 | 90 | Palliative (P) | null | null | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101108021 |
| 160015339 | 160007598 | 1.78 | 70.9 | 03 | 2018-11-05 | 2018-11-18 | Doxorubicin 75mg/m2 | 02 | N | EW EUROEWING 2012 ARM B VDC | 100091203 |
| 160015341 | 160007599 | 1.75 | 89.2 | Palliative (P) | 2017-06-23 | 2017-06-26 | Doxorubicin + Ifosfamide | 02 | N | CISPLATIN + PACLITAXEL | 100707005 |
| 160015342 | 160007600 | 1.77 | 96.9 | Adjuvant (A) | 2016-02-19 | 2016-02-20 | null | 02 | null | EW EUROEWING 2012 ARM A VIDE | 101289092 |
| 160015343 | 160007601 | null | 67.3 | null | 2019-10-22 | 2019-11-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100568238 |
| 160015344 | 160007602 | null | 48.8 | Palliative (P) | 2018-08-14 | 2018-08-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100205875 |
| 160015345 | 160007603 | 1.61 | 78.2 | Palliative (P) | 2017-05-27 | 2017-05-27 | Bevacizumab+Carbo+Pacliaxel | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100977900 |
| 160015347 | 160007604 | 1.64 | 22 | null | null | 2021-09-05 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | N | DOXORUBICIN | 101648287 |
| 160015349 | 160007605 | 1.78 | 74.9 | Neo-adjuvant (N) | 2016-04-11 | 2016-04-21 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101011241 |
| 160015350 | 160007606 | 0 | 19.5 | Palliative (P) | 2017-12-08 | 2017-12-14 | Liposomal Doxorubicin (Caelyx) | 01 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101403175 |
| 160015352 | 160007607 | 1.73 | 71 | Palliative (P) | 2016-05-13 | 2016-05-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100261820 |
| 160015355 | 160007608 | 1.71 | 115 | Palliative (P) | 2018-12-29 | 2018-12-29 | Doxorubicin 75mg/m2 | N | N | DOXORUBICIN | 100076847 |
| 160015356 | 160007609 | 1.63 | 56.6 | null | 2017-11-06 | 2017-11-06 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | CARBOPLATIN + PACLITAXEL | 101248320 |
| 160015357 | 160007610 | 1.63 | 51.5 | Palliative (P) | 2018-12-28 | 2019-01-03 | ETOPOSIDE + IFOSFAMIDE | null | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101862559 |
| 160015358 | 160007611 | 1.66 | 55.8 | Palliative (P) | 2018-12-12 | 2018-12-12 | Liposomal Doxorubicin (Caelyx) | 02 | N | DOXORUBICIN | 101731233 |
| 160015363 | 160007612 | 1.88 | 113.1 | 03 | null | null | IVA | N | N | ETOP 13-18 BEAT-MESO TRIAL | 101490726 |
| 160015365 | 160007613 | 1.75 | 76.9 | Palliative (P) | null | 2019-12-22 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100493687 |
| 160015369 | 160007615 | 1.62 | 93 | Palliative (P) | 2017-02-05 | 2019-10-03 | Trial Unspecified | 02 | N | EW EUROEWING 2012 ARM B VDC | 100636134 |
| 160015372 | 160007616 | 1.78 | 62.9 | null | 2020-03-04 | 2020-03-04 | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN + OLARATUMAB | 101420929 |
| 160015378 | 160007617 | 1.61 | 65.1 | Palliative (P) | 2017-06-23 | 2017-07-13 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN + OLARATUMAB | 100356244 |
| 160015379 | 160007618 | 1.61 | 79 | null | 2017-03-13 | 2017-04-09 | DOCETAXEL + GEMCITABINE | null | null | VINCRISTINE | 100910842 |
| 160015380 | 160007619 | 1.77 | 87.6 | 03 | 2017-11-24 | 2017-12-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100115524 |
| 160015383 | 160007620 | null | null | null | null | 2019-02-22 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | DOXORUBICIN + OLARATUMAB | 101253053 |
| 160015385 | 160007621 | 1.78 | 64.6 | Palliative (P) | 2017-03-30 | 2017-04-09 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100916339 |
| 160015387 | 160007622 | 1.6 | 81.9 | Palliative (P) | null | 2018-10-26 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101839590 |
| 160015392 | 160007623 | 1.7 | 66 | Neo-adjuvant (N) | 2017-07-19 | 2017-07-19 | Epirubicin (weekly) | 01 | N | LIPOSOMAL DOXORUBICIN | 101583893 |
| 160015394 | 160007624 | 1.76 | 96.6 | Palliative (P) | 2018-08-22 | 2018-08-22 | Paclitaxel 80mg/m2 day 1 8 15 | n | N | TRIAL | 101565022 |
| 160015397 | 160007625 | 1.58 | 58.3 | Palliative (P) | 2018-03-10 | 2018-03-10 | GemCarbo Days 1+8 | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100431389 |
| 160015399 | 160007626 | 1.75 | 59 | Palliative (P) | 2019-08-05 | 2019-10-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100409630 |
| 160015401 | 160007627 | 0.76 | 72.25 | Palliative (P) | 2021-02-15 | 2021-02-24 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | null | PACLITAXEL | 100282799 |
| 160015402 | 160007628 | 1.75 | 64.6 | Palliative (P) | 2020-02-01 | 2020-02-02 | EW EuroEwing 2012 Arm B VDC | 02 | N | CISPLATIN + ETOPOSIDE | 101134270 |
| 160015403 | 160007629 | 1.77 | 65 | Palliative (P) | 2018-04-13 | 2018-04-26 | EW EuroEwing 2012 Arm A VIDE | 02 | N | EW EUROEWING 2012 ARM A VAI | 101789005 |
| 160015404 | 160007630 | 1.67 | 90.3 | Palliative (P) | 2019-07-07 | 2019-07-14 | Enzalutamide | 02 | null | EW EUROEWING 2012 ARM A VIDE | 101148921 |
| 160015406 | 160007631 | 1.58 | 66 | Disease modification (D) | 2018-07-15 | 2018-07-29 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100947456 |
| 160015408 | 160007632 | null | null | Palliative (P) | 2019-09-21 | 2019-09-29 | VDC | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100543165 |
| 160015411 | 160007633 | 1.77 | 58 | Palliative (P) | 2017-04-01 | 2017-04-01 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100887688 |
| 160015412 | 160007634 | 1.59 | 56.4 | 03 | 2017-08-29 | 2017-09-17 | Liposomal Doxorubicin (Caelyx) | N | N | NOT MATCHED | 100477131 |